Pharmaceutical Strategy Consulting

Tailored solutions for successful pharmaceutical development and market access in China and across the Asia Pacific region.

China and the Asia Pacific region offer vast opportunities for pharmaceutical companies, but navigating these markets requires deep regulatory insight, clinical development expertise, and strategic foresight. Cisema supports international life sciences organizations with customized consulting services that span the full product lifecycle, from early-stage development to successful commercialization.

With over 20 years of regional expertise, we help ensure that your medical products meet evolving regulatory requirements, accelerate drug development timelines and achieve market access across diverse APAC jurisdictions. Our integrated approach combines regulatory strategy, clinical development support, and operational execution - tailored to the needs of start-ups, mid-size companies, and global pharmaceutical leaders.

Pharmaceutical Strategy Consulting
Cisema helping innovative products from research into commercialization
Life Sciences Consulting

We align regulatory compliance with business strategy, helping clients build capabilities and seize emerging growth opportunities. Whether you're preparing for clinical trials, navigating NMPA submissions, or expanding across ASEAN, South Korea, Japan, or Australia, our bilingual teams across Europe and Asia deliver accurate, timely, and compliant submissions.

Cisema’s consulting services are designed to support biotech innovators, life sciences companies, academia and clinical research organizations with strategic planning, data analytics, and regulatory intelligence. We work across the value chain - from clinical development to post-market lifecycle management - to define stakeholder value, optimize resource allocation, and improve patient outcomes.

Our China & APAC Pharmaceutical Consulting Services:

Whether you’re entering China or an APAC market for the first time, scaling operations, or seeking support during early-stage development, Cisema provides strategic guidance and regional regulatory expertise to help you navigate every phase of the pharmaceutical product lifecycle. With over 20 years of experience, we empower life sciences companies to make informed decisions and capture growth opportunities across Asia Pacific’s dynamic healthcare landscape.

Drug Development Strategy & Planning

We design development strategies that align clinical, regulatory, and commercial milestones with the diverse market conditions across Asia Pacific. Our roadmaps streamline submissions, eliminate barriers, and optimize resource allocation from concept to launch.

Regulatory & Clinical GAP Analysis

Our experts assess your documentation for alignment with local regulatory and clinical requirements. We identify gaps and provide actionable recommendations to support both innovative and generic drug submissions, reducing risk and improving approval efficiency.

Expedited Approval Pathways

We help you leverage fast-track designations, priority reviews, and conditional approvals available in China and other Asia Pacific markets. Our team guides you through eligibility assessments and application preparation to accelerate time to market.

Regulatory Authority Engagement & Submission Preparation

Acting as your liaison with national health authorities, we manage regulatory interactions, prepare submission-ready technical documentation, and ensure alignment with local standards for a smooth review process

Clinical Trial Strategy & Local Study Design

We evaluate the acceptability of foreign clinical data and determine the need for local trials. Our experts support protocol design, site selection, and operational management to ensure compliant and efficient clinical development.

Regulatory, Scientific & Medical Writing

We prepare high-quality documentation, including CTD modules, clinical summaries, and safety narratives, tailored to local regulatory expectations. Clear, well-structured submissions improve engagement with authorities and facilitate faster approvals.

Market Access & Commercial Strategy

Post-approval, we help position your product for commercial success through:

Pricing & Reimbursement: Including National Reimbursement Drug List pathway insights and health economics modeling.
Stakeholder Mapping: Engaging payers, Key Opinion Leaders, and hospital channels.
Competitor Benchmarking: Tailoring your value proposition to local market dynamics.

Why Work with Cisema?

Local expertise with global reach

Our bilingual teams bridge international quality standards with local regulations

Proven track record

Over 20 years supporting market approvals and compliance in China and Asia Pacific

End-to-end solutions

From system setup to post-market surveillance, we ensure quality management and regulatory compliance throughout the product lifecycle

Industry breadth

Cross-sector expertise in life sciences, food, veterinary, consumer and industrial goods

Role of a China Agent

Frequently Asked Questions

Common hurdles include data localization, fragmented and frequent regulatory updates, and strict post-market obligations. We help you address these early with clear strategies that reduce approval timelines and costs.

Early communication with national authorities clarifies requirements and minimizes risk. Our experts support pre-submission meetings, technical reviews, and strategic planning to set your submission up for success.

We assess eligibility and manage the entire process, from dossier preparation to interactions with regulators, to maximize your product’s chances of accelerated review.

Trials must meet local regulatory, ethical, and cultural expectations. We help design trials that comply with each country’s standards, leverage foreign data where applicable, and avoid delays.

We assist with pharmacovigilance, lifecycle management, and updates to maintain compliance with evolving regulations and market requirements.

Request a Proposal from Our Pharma Team

Let Cisema help turn your plans into reality.

Request Proposal

Explore Related Services

Pharmaceutical Regulatory Affairs

Navigate regulatory complexity across China and Asia Pacific with confidence. Our regulatory affairs consulting experts support life sciences companies with strategic planning, compliant submissions, and local representation to accelerate approvals and ensure market readiness.

Learn more

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consulting experts help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Learn more

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Learn more

Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences companies strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

Learn more

Read the Latest Regulatory News

View More

Indonesia Mandates Pre-Shipment Halal Verification for Imported Products

BPJPH Regulation No. 4 of 2026 introduces pre-shipment halal verification and LPPH reports for imported goods starting September 2026.

September 25, 2026
Indonesia Mandates Pre-Shipment Halal Verification for Imported Products

TFDA Updates Processing Time Limits for Public Applications in Taiwan

Taiwan's TFDA has revised its processing time limits table for public applications, adding eight application items and amending two existing items.

September 9, 2026
TFDA Updates Processing Time Limits for Public Applications in Taiwan

China Proposes ICH E6(R3) Annex 2 Compliance for Clinical Trials from 2027

China proposes ICH E6(R3) Annex 2 implementation from January 2027, with public comments open for one month from August 10 2026.

August 31, 2026
China Proposes ICH E6(R3) Annex 2 Compliance for Clinical Trials from 2027

Guangdong MPA Implements 2026 Guideline for Importing Hong Kong and Macao Drugs into the Greater Bay Area

The guideline introduces more detailed evidence requirements for Hong Kong and Macao drug imports while retaining a streamlined pathway for products already approved under the GBA Connect scheme.

August 31, 2026
Guangdong MPA Implements 2026 Guideline for Importing Hong Kong and Macao Drugs into the Greater Bay Area

CDE Proposes Revised Standards for Written Supplementary Information Requests

The draft clarifies when CDE may issue written supplementary information requests and when major deficiencies identified during review may instead lead to a non-approval conclusion.

August 24, 2026
CDE Proposes Revised Standards for Written Supplementary Information Requests

Beijing Establishes Ongoing Whitelist Scheme for Biopharmaceutical R&D Material Imports

The R&D import whitelist scheme streamlines customs clearance while maintaining specific eligibility, traceability, and risk-control requirements.

August 24, 2026
Beijing Establishes Ongoing Whitelist Scheme for Biopharmaceutical R&D Material Imports
Previous
Previous

Get in Touch with Our Pharma Consultants

Speak with our pharma consultants to explore how our regulatory services, operational capabilities, and strategic expertise can help your organization navigate the region's complex pharmaceutical markets.

Request Proposal